WO2011037550A3 - Dry powder combination of tiotropium - Google Patents

Dry powder combination of tiotropium Download PDF

Info

Publication number
WO2011037550A3
WO2011037550A3 PCT/TR2010/000184 TR2010000184W WO2011037550A3 WO 2011037550 A3 WO2011037550 A3 WO 2011037550A3 TR 2010000184 W TR2010000184 W TR 2010000184W WO 2011037550 A3 WO2011037550 A3 WO 2011037550A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
dry powder
powder combination
combination
formulated
Prior art date
Application number
PCT/TR2010/000184
Other languages
French (fr)
Other versions
WO2011037550A2 (en
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Priority to EP10787588A priority Critical patent/EP2480287A2/en
Publication of WO2011037550A2 publication Critical patent/WO2011037550A2/en
Publication of WO2011037550A3 publication Critical patent/WO2011037550A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

The present invention relates to a pharmaceutical composition containing tiotropium formulated with an effective amount of a cromolyn derivative used for the treatment of respiratory disease by inhalation route.
PCT/TR2010/000184 2009-09-23 2010-09-22 Dry powder combination of tiotropium WO2011037550A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10787588A EP2480287A2 (en) 2009-09-23 2010-09-22 Dry powder combination of tiotropium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/07237 2009-09-23
TR2009/07237A TR200907237A2 (en) 2009-09-23 2009-09-23 Tiotropium dry powder combination

Publications (2)

Publication Number Publication Date
WO2011037550A2 WO2011037550A2 (en) 2011-03-31
WO2011037550A3 true WO2011037550A3 (en) 2011-09-15

Family

ID=43643869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000184 WO2011037550A2 (en) 2009-09-23 2010-09-22 Dry powder combination of tiotropium

Country Status (3)

Country Link
EP (1) EP2480287A2 (en)
TR (1) TR200907237A2 (en)
WO (1) WO2011037550A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2204790A (en) * 1987-05-23 1988-11-23 Fisons Plc Nedocromil compositions and salts
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2002036591A2 (en) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative solution formulation containing a tiotropium salt
WO2006076222A2 (en) * 2005-01-10 2006-07-20 Glaxo Group Limited Pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
GB9006233D0 (en) 1990-03-20 1990-05-16 Kenrick & Jefferson Ltd Forms,for use,for example,as parking tickets
PT1102579E (en) * 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2204790A (en) * 1987-05-23 1988-11-23 Fisons Plc Nedocromil compositions and salts
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2002036591A2 (en) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative solution formulation containing a tiotropium salt
WO2006076222A2 (en) * 2005-01-10 2006-07-20 Glaxo Group Limited Pharmaceutical formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Anti-cholinergic compounds", RESEARCH DISCLOSURE, MASON PUBLICATIONS, HAMPSHIRE, GB, vol. 227, no. 17, 1 March 1983 (1983-03-01), XP007108764, ISSN: 0374-4353 *
See also references of EP2480287A2 *

Also Published As

Publication number Publication date
WO2011037550A2 (en) 2011-03-31
EP2480287A2 (en) 2012-08-01
TR200907237A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
ZA201303960B (en) Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
EP2415749A4 (en) New salvianolic acid compound l, preparation method and use thereof
HK1160034A1 (en) Pharmaceutical composition for inhalation
IL212720A (en) Composition for buccal absorption of nicotine for the purpose of smoking cessation
EA201291306A1 (en) COMPOSITION OF DRY POWDER CONTAINING ANTIMUSCARINE MEANS
DK3284459T3 (en) Pharmaceutical compositions comprising a local anaesthetic such as Bupivacaine for local administration to the mouth or throat
ZA201207634B (en) Pharmaceutical powder composition for inhalation
PT2236149E (en) Medicinal composition for treating respiratory infectious diseases
HK1186671A1 (en) Formulations for the treatment of disorders of the upper respiratory tract
HK1194302A1 (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
WO2011152804A3 (en) Process for dry powder formulations
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
EP2594283A4 (en) Aprotinin-based aerosol preparation for the treatment of viral respiratory infections
EP2368548A4 (en) Dry powder pharmaceutical composition for inhalation
WO2010101538A3 (en) New crystalline forms of tiotropium bromide
WO2011037550A3 (en) Dry powder combination of tiotropium
ZA201207696B (en) Compound for treatment of respiratory condition or disease
TR200909789A2 (en) Dry powder combination containing tiotropium, budesonide and a chromoglycic acid derivative combination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10787588

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010787588

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010787588

Country of ref document: EP